KPTI
insider transactionsKaryopharm Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-37.6K
0 buy · 37.6K sell
Net value · 365d
-$347.9K
$0 in · $347.9K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
17
0 buy · 37.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own New
-
Grant·A
Director
$0
15.5K sh
Own +1710%
-
Sell·S
EVP, Chief Development Officer
$3.8K
403 sh · $9.50
Own -0%
-
Sell·S
EVP & Chief Medical Officer
$3.9K
408 sh · $9.50
Own -1%
-
Sell·S
President and CEO
$20.9K
2.2K sh · $9.50
Own -1%
-
Sell·S
EVP, CLO&Secretary
$2.5K
266 sh · $9.50
Own -0%
-
Sell·S
EVP & Chief Commercial Officer
$3.1K
324 sh · $9.50
Own -0%
-
Sell·S
Chief Accounting Officer
$504
53 sh · $9.50
Own -0%
-
Grant·A
EVP, Chief Development Officer
$0
896 sh
Own +1%
-
Grant·A
EVP & Chief Medical Officer
$0
947 sh
Own +2%
-
Grant·A
President and CEO
$0
4.9K sh
Own +2%
-
Grant·A
EVP, CLO&Secretary
$0
700 sh
Own +1%
-
Grant·A
EVP & Chief Commercial Officer
$0
947 sh
Own +1%
-
Grant·A
Chief Accounting Officer
$0
121 sh
Own +1%
-
Sell·S
EVP & Chief Medical Officer
$4.0K
449 sh · $8.94
Own -1%
-
Sell·S
EVP, Chief Development Officer
$48.0K
5.1K sh · $9.41
Own -5%
-
Sell·S
EVP, CLO&Secretary
$33.2K
3.5K sh · $9.41
Own -4%
-
Sell·S
EVP & Chief Medical Officer
$47.7K
5.1K sh · $9.41
Own -8%
-
Sell·S
President and CEO
$116.3K
12.4K sh · $9.41
Own -4%
-
Sell·S
EVP & Chief Commercial Officer
$43.3K
4.6K sh · $9.41
Own -4%
-
Sell·S
Chief Accounting Officer
$5.3K
559 sh · $9.41
Own -2%
-
Sell·S
EVP, Chief Development Officer
$3.3K
378 sh · $8.63
Own -0%
-
Grant·A
President and CEO
$0
81.1K sh
Own +41%
-
Sell·S
Lori Macomber KEY
EVP, CFO & Treasurer
$10.2K
1.6K sh · $6.30
Own -2%
-
Grant·A
EVP & Chief Medical Officer
$0
32.4K sh
Own +110%
-
Grant·A
Lori Macomber KEY
EVP, CFO & Treasurer
$0
32.4K sh
Own +60%
-
Grant·A
EVP, CLO&Secretary
$0
32.4K sh
Own +50%
-
Grant·A
EVP, Chief Development Officer
$0
32.4K sh
Own +48%
-
Grant·A
EVP & Chief Commercial Officer
$0
32.4K sh
Own +41%
-
Sell·S
Chief Accounting Officer
$352
50 sh · $7.03
Own -0%
-
Grant·A
Chief Accounting Officer
$0
92 sh
Own +0%
-
Sell·S
Chief Accounting Officer
$1.6K
265 sh · $5.96
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Zhen Su | Grant A | 15.5K | $0 |
| May 21, 2026 | Christy J. Oliger | Grant A | 15.5K | $0 |
| May 21, 2026 | Chen Schor | Grant A | 15.5K | $0 |
| May 21, 2026 | Deepika Pakianathan | Grant A | 15.5K | $0 |
| May 21, 2026 | Barry E Greene | Grant A | 15.5K | $0 |
| May 14, 2026 | Stuart Poulton | Sell S | 403 | $3.8K |
| May 14, 2026 | Reshma Rangwala | Sell S | 408 | $3.9K |
| May 14, 2026 | Richard A. Paulson KEY | Sell S | 2.2K | $20.9K |
| May 14, 2026 | Michael Mano | Sell S | 266 | $2.5K |
| May 14, 2026 | Sohanya Roshan Cheng | Sell S | 324 | $3.1K |
| May 14, 2026 | Kristin Abate | Sell S | 53 | $504 |
| May 13, 2026 | Stuart Poulton | Grant A | 896 | $0 |
| May 13, 2026 | Reshma Rangwala | Grant A | 947 | $0 |
| May 13, 2026 | Richard A. Paulson KEY | Grant A | 4.9K | $0 |
| May 13, 2026 | Michael Mano | Grant A | 700 | $0 |
| May 13, 2026 | Sohanya Roshan Cheng | Grant A | 947 | $0 |
| May 13, 2026 | Kristin Abate | Grant A | 121 | $0 |
| Apr 21, 2026 | Reshma Rangwala | Sell S | 449 | $4.0K |
| Mar 2, 2026 | Stuart Poulton | Sell S | 5.1K | $48.0K |
| Mar 2, 2026 | Michael Mano | Sell S | 3.5K | $33.2K |
| Mar 2, 2026 | Reshma Rangwala | Sell S | 5.1K | $47.7K |
| Mar 2, 2026 | Richard A. Paulson KEY | Sell S | 12.4K | $116.3K |
| Mar 2, 2026 | Sohanya Roshan Cheng | Sell S | 4.6K | $43.3K |
| Mar 2, 2026 | Kristin Abate | Sell S | 559 | $5.3K |
| Feb 17, 2026 | Stuart Poulton | Sell S | 378 | $3.3K |
| Feb 5, 2026 | Richard A. Paulson KEY | Grant A | 81.1K | $0 |
| Feb 3, 2026 | Lori Macomber KEY | Sell S | 1.6K | $10.2K |
| Jan 31, 2026 | Reshma Rangwala | Grant A | 32.4K | $0 |
| Jan 31, 2026 | Lori Macomber KEY | Grant A | 32.4K | $0 |
| Jan 31, 2026 | Michael Mano | Grant A | 32.4K | $0 |
| Jan 31, 2026 | Stuart Poulton | Grant A | 32.4K | $0 |
| Jan 31, 2026 | Sohanya Roshan Cheng | Grant A | 32.4K | $0 |
| Jan 28, 2026 | Kristin Abate | Sell S | 50 | $352 |
| Jan 27, 2026 | Kristin Abate | Grant A | 92 | $0 |
| Jan 21, 2026 | Kristin Abate | Sell S | 265 | $1.6K |
About KPTI insider trading
This page tracks insider transactions for Karyopharm Therapeutics Inc. (KPTI) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.